GoodRx Chief Accounting Officer Resigns for New Opportunity

The latest announcement is out from GoodRx Holdings ( (GDRX) ).

On March 24, 2026, GoodRx Holdings, Inc. announced that Chief Accounting Officer Romin Nabiey submitted his resignation, effective April 3, 2026, to pursue other opportunities, in a move that the company said was not related to any disagreement over its operations, policies, or practices. Nabiey will remain with GoodRx as an employee through June 8, 2026, to support the transition of his responsibilities, as the company acknowledges his years of contribution and works to maintain continuity in its finance and accounting functions.

The most recent analyst rating on (GDRX) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on GoodRx Holdings stock, see the GDRX Stock Forecast page.

Spark’s Take on GDRX Stock

According to Spark, TipRanks’ AI Analyst, GDRX is a Neutral.

The score is driven primarily by improved financial stability (profitability rebound, consistent cash generation, and sharply reduced leverage), partially offset by weak price trends and a transitional earnings outlook where 2026 guidance points to revenue/EBITDA declines and continued pressure in the core prescription transactions business. Valuation is supportive but not strong enough to outweigh near-term growth and momentum risks.

To see Spark’s full report on GDRX stock, click here.

More about GoodRx Holdings

GoodRx Holdings, Inc. operates in the healthcare and digital health industry, focusing on providing consumers with tools to find lower prescription drug prices and access healthcare services more affordably. The company’s platform connects users, pharmacies, and providers, positioning GoodRx as a key player in price transparency and savings within the U.S. prescription market.

Average Trading Volume: 3,148,109

Technical Sentiment Signal: Sell

Current Market Cap: $698.9M

For an in-depth examination of GDRX stock, go to TipRanks’ Overview page.